Carlos A Q Santos1, Daniel C Brennan, Roger D Yusen, Margaret A Olsen. 1. 1 Division of Infectious Diseases, Department of Medicine, Washington University School of Medicine, St. Louis, MO. 2 Division of Renal Diseases, Department of Medicine, Washington University School of Medicine, St. Louis, MO. 3 Division of Pulmonary and Critical Care Medicine, Department of Medicine, Washington University School of Medicine, St. Louis, MO. 4 Division of Public Health Sciences, Department of Surgery, Washington University School of Medicine, St. Louis, MO.
Abstract
BACKGROUND: Cytomegalovirus (CMV) replication and disease commonly occur in lung transplant recipients after stopping anti-CMV prophylaxis. The epidemiology of CMV disease is not well studied, given the difficulties in assembling representative study populations with prolonged follow-up. We hypothesized that delayed-onset CMV disease (>100 days after transplantation) occurs more commonly than early-onset CMV disease in lung transplant recipients, and is associated with an increased risk of death. METHODS: We assembled a large cohort of lung transplant recipients using 2004 to 2010 International Classification of Diseases, Ninth Revision, Clinical Modification billing data from 3 Agency for Healthcare Research and Quality State Inpatient Databases, and identified demographics, comorbidities, CMV disease coded during hospital readmission and inpatient death. We used Cox proportional hazard multivariate analyses to assess for an independent association between delayed-onset CMV disease and death. RESULTS: In the cohort of 1528 lung transplant recipients from 12 transplant centers, delayed-onset CMV disease occurred in 13.7% (n = 210) and early-onset CMV disease occurred in 3.3% (n = 51). Delayed-onset CMV pneumonitis was associated with inpatient death longer than 100 days after transplantation (adjusted hazard ratio, 1.6; 95% confidence interval [95% CI], 1.1-2.5), after adjusting for transplant failure/rejection (aHR, 2.5; 95% CI, 1.5-4.1), bacterial pneumonia (aHR, 2.8; 95% CI, 2.0-3.9), viral pneumonia (aHR, 1.5; 95% CI, 1.1-2.1), fungal pneumonia (aHR, 1.8; 95% CI, 1.3-2.3), single lung transplant (aHR, 1.3; 95% CI, 1.0-1.7), and idiopathic pulmonary fibrosis (aHR, 1.4; 95% CI, 1.0-1.8). CONCLUSIONS: Delayed-onset CMV disease occurred more commonly than early-onset CMV disease among lung transplant recipients. These results suggest that delayed-onset CMV pneumonitis was independently associated with an increased risk of death.
BACKGROUND:Cytomegalovirus (CMV) replication and disease commonly occur in lung transplant recipients after stopping anti-CMV prophylaxis. The epidemiology of CMV disease is not well studied, given the difficulties in assembling representative study populations with prolonged follow-up. We hypothesized that delayed-onset CMV disease (>100 days after transplantation) occurs more commonly than early-onset CMV disease in lung transplant recipients, and is associated with an increased risk of death. METHODS: We assembled a large cohort of lung transplant recipients using 2004 to 2010 International Classification of Diseases, Ninth Revision, Clinical Modification billing data from 3 Agency for Healthcare Research and Quality State Inpatient Databases, and identified demographics, comorbidities, CMV disease coded during hospital readmission and inpatient death. We used Cox proportional hazard multivariate analyses to assess for an independent association between delayed-onset CMV disease and death. RESULTS: In the cohort of 1528 lung transplant recipients from 12 transplant centers, delayed-onset CMV disease occurred in 13.7% (n = 210) and early-onset CMV disease occurred in 3.3% (n = 51). Delayed-onset CMV pneumonitis was associated with inpatient death longer than 100 days after transplantation (adjusted hazard ratio, 1.6; 95% confidence interval [95% CI], 1.1-2.5), after adjusting for transplant failure/rejection (aHR, 2.5; 95% CI, 1.5-4.1), bacterial pneumonia (aHR, 2.8; 95% CI, 2.0-3.9), viral pneumonia (aHR, 1.5; 95% CI, 1.1-2.1), fungal pneumonia (aHR, 1.8; 95% CI, 1.3-2.3), single lung transplant (aHR, 1.3; 95% CI, 1.0-1.7), and idiopathic pulmonary fibrosis (aHR, 1.4; 95% CI, 1.0-1.8). CONCLUSIONS: Delayed-onset CMV disease occurred more commonly than early-onset CMV disease among lung transplant recipients. These results suggest that delayed-onset CMV pneumonitis was independently associated with an increased risk of death.
Authors: R R Razonable; A Rivero; A Rodriguez; J Wilson; J Daniels; G Jenkins; T Larson; W C Hellinger; J R Spivey; C V Paya Journal: J Infect Dis Date: 2001-10-23 Impact factor: 5.226
Authors: Marc Estenne; Janet R Maurer; Annette Boehler; James J Egan; Adaani Frost; Marshall Hertz; George B Mallory; Gregory I Snell; Samuel Yousem Journal: J Heart Lung Transplant Date: 2002-03 Impact factor: 10.247
Authors: Claire L Gordon; Michelle Miron; Joseph J C Thome; Nobuhide Matsuoka; Joshua Weiner; Michael A Rak; Suzu Igarashi; Tomer Granot; Harvey Lerner; Felicia Goodrum; Donna L Farber Journal: J Exp Med Date: 2017-01-27 Impact factor: 14.307
Authors: Aurora Paez-Vega; Sara Cantisan; José Manuel Vaquero; Elisa Vidal; Antonio Luque-Pineda; María Ángeles Lobo-Acosta; Ana Belén Pérez; Rodrigo Alonso-Moralejo; David Iturbe; Victor Monforte; Isabel Otero-Gonzalez; Amparo Pastor; Piedad Ussetti; Julian Torre-Cisneros Journal: BMJ Open Date: 2019-08-15 Impact factor: 2.692
Authors: Coretta C Van Leer Buter; Danielle W K de Voogd; Hans Blokzijl; Anoek A E de Joode; Stefan P Berger; Erik A M Verschuuren; Hubert G M Niesters Journal: J Antimicrob Chemother Date: 2019-08-01 Impact factor: 5.790